Press Releases

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 12/03/09 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), is scheduled to be presented as a poster presentation at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS) to be held December 9-13, 2009 at the Henry B. Gonzalez Convention Center, San Antonio, Texas. GSK-923295 is currently being studied in a GlaxoSmithKline sponsored Phase I, first time in humans clinical trial designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of this novel drug candidate in patients with advanced, refractory solid tumors.

Poster Presentation at SABCS

Abstract #2020: "A Systems Analysis of Mitotic Apparatus Inhibitors Defines a Response Network for Breast Cancer" is scheduled to be displayed as a poster presentation on Friday, December 11, 2009 in Poster Session 2. The presentation will be made by Zhi Hu, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA from 7:00 AM - 9:00 AM Central Time in Exhibit A-B in the Henry B. Gonzalez Convention Center.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is in Phase I clinical development. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates in Phase I clinical development: ispinesib, SB-743921 and GSK-923295. Cytokinetics is seeking a partner for ispinesib and SB-743921. GSK-923295 is being developed by GlaxoSmithKline in collaboration with Cytokinetics. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission

Contacts:
Cytokinetics, Incorporated
Christopher S. Keenan (Investors and Media)
Director, Investor Relations
(650) 624-3000

TSX-V: TTQ

Frankfurt Stock Exchange Symbol: T2U

US Clearing Symbol: TTMRF

Issued and Outstanding: 46,329,989

VANCOUVER, Dec. 3 /PRNewswire-FirstCall/ - TTM Resources Inc. (TSX-V:TTQ, Frankfurt: T2U)

Private Placement

TTM Resources Inc. ("TTM" or the "Company") is pleased to announce the closing of its recently announced non-brokered private placement. The Company issued an aggregate of 3,000,000 flow-through units at a price of $0.40 per unit for gross proceeds of $1,200,000. Each flow-through unit consists of one flow-through common share and one share purchase warrant which entitles the holder to purchase an additional non flow-through common share of the Company at a price of $0.50 until December 3, 2011. The shares, warrants and warrant shares are subject to a four month hold period.

The Company paid finder's fees in the amount of $10,000 in connection with the private placement.

The proceeds of the private placement will be used to fund the Company's resource exploration on the Chu Molybdenum Development Project. Diamond Drilling on the Company's Chu Project is now in progress.

Annual General Meeting

The Company is also pleased to announce that its shareholders approved all matters presented at the Annual General Meeting held on December 1, 2009.

TTM's shareholders re-elected Crichy Clarke, Terry Lyons, Richard Jordens, David McMillan, Robert Sibthorpe and Warren Robb to the Board of Directors. Each shall serve as a Director of the Company until the 2010 Annual General Meeting.

Shareholders of the Company also re-appointed Smythe Ratcliffe, Chartered Accountants as auditors for the ensuing year and approved the adoption of the 2009 20% Stock Option Plan, the particulars of which are set out in more detail in the Company's Management Information Circular dated October 20, 2009.

About TTM Resources Inc.

TTM Resources Inc. is a Vancouver, British Columbia based Molybdenum Development and Exploration Company focused on the resource development of the Chu Molybdenum Project and three other molybdenum properties in British Columbia, Canada.

    TTM RESOURCES INC.
    "Crichy Clarke"
    ------------------
    W.K. Crichy Clarke
    President & CEO

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INFORMATION

This news release contains certain "forward-looking information" within the meaning of Canadian securities laws. Actual results may differ materially from those indicated by such forward-looking information. All information included herein, other than statements of historical fact, including, without limitation, information regarding future production, is considered forward-looking information and involves various risks and uncertainties. There can be no assurance that the forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE TTM Resources Inc.

DETROIT, Dec. 3 /PRNewswire/ -- With winter weather coming to much of the country, the scrunch, scrunch, scrunch sound of scraping ice from the windshield leaves most people cold - literally and figuratively.

On most 2010 Chevrolet models, a factory-installed remote start option makes winter temperatures a lot easier to take. The factory-installed option has been available since the 2004 model year and, depending on the model, costs $300 or less.

"Chevrolet customers tell us they love this feature, because it makes their lives a little easier," said Chuck Bongiorno, GM's engineering group manager for vehicle access, starting and security. "On a cold winter morning, a customer's Malibu or Equinox can be toasty inside and the windows defrosted before they get in their car to head off to work."

Remote start also can reduce overall emissions versus a cold-start drive-away because as the idling engine warms, it activates the catalyst that traps unburned hydrocarbons.

And no need to worry about a car thief jumping in and driving off. The vehicle doors are locked while remote start is running. Remote start runs for 10 minutes and then shuts off, unless the driver extends the time up to 20 minutes.

The Chevrolet remote start system makes sure the vehicle is operating properly every time it is started. The system checks to be sure the hood is closed, via a hood switch and conducts a host of vehicle diagnostics.

Using the remote start system is easy. First, the driver presses the "LOCK" button on their key fob, locking the doors. Then the driver presses and holds the remote start button on the fob for one and a half seconds. This two-step process helps prevent inadvertent activation and assures the vehicle is locked. To signify the remote start system received the signal, the vehicle's signal lamps flash once. When the engine begins running, the parking lamps illuminate.

"The system in the Chevrolet lineup is superior to any on the market because it is integrated into the vehicle's electrical, theft and safety systems," said Scott McCullough, the GM lead subsystem engineer on the system. "A fully integrated system enhances vehicle quality and reliability while offering customers a more price competitive option."

Ford currently offers a dealer-installed, after market system that costs nearly $400. Toyota's remote start system costs more than $500.

Introduced in 2003, the Chevrolet remote start system is offered on the 2010 Silverado, Avalanche, Tahoe, Suburban, Traverse, Impala, Malibu, Cobalt, HHR, Camaro, Equinox and Express models.

SOURCE General Motors

NEW YORK--(BUSINESS WIRE)-- Fitch Ratings has upgraded one tranche and downgraded three tranches of notes issued by Structured Enhanced Return Vehicle Trust, series 2006-1 (SERVES 2006-1). Additionally, two tranches have been affirmed by Fitch. A detailed list of rating actions follows at the end of this press release.

The rating actions reflect Fitch's analysis of both the market value (MV) and the credit risk of the portfolio. Given the exposure to both risks, the tranches are rated to the lower of the two indicative levels.

The market value risk was analyzed by comparing the distance-to-trigger (DTT) metric and distance-from-trigger (DFT) metric to the advance rate ranges published in Fitch's Market Value Structures criteria and further supplemented in 'Fitch Update: Application of Revised Market Value Structure Criteria to TRR CLOs', published in May 2008. Also, as the reference portfolio is comprised of a diverse pool of senior secured loans, the credit risk of the portfolio was analyzed using the Portfolio Credit Model (PCM), as described in Fitch's Corporate CDO criteria (this and the other aforementioned criteria are cited at the bottom of this press release).

Based on Fitch's PCM analysis, the par subordination of the class A notes (approximately 32%) is in line with a 'AAA' rating loss rate, based on Fitch's PCM result. However, reflecting Fitch's classification of the assets, the market value trigger for the class A tranches is in line with Fitch's 'B' advance rates for this structure, with a combined DFT and DTT metric of approximately 19%. Therefore, the ratings for the class A-1 notes have been affirmed at 'B' and the ratings for the class A-2 notes have been upgraded to 'B', as significant credit risk is present in both tranches, but a limited margin of safety remains on a market value basis. Due to the MV coverage cushion available to this class, which is at the high end of the 'B' range, the notes have been assigned a Stable Outlook by Fitch. Note that the class A-1 notes are currently undrawn.

Based on the classification of the assets, the market value trigger for the class B notes is in line with Fitch's 'B' advance rates, with a DTT metric of approximately 13%. The par subordination of the class B notes (approximately 7%), however, is less than the 'CCC' rating loss rate based on Fitch's PCM result, which is the minimum supported output in Fitch's PCM. Therefore, the rating has been affirmed at 'CC', as default of some kind appears probable.

The class C and class D notes have negative market value and par subordination, and are therefore unlikely to see any principal proceeds at maturity. Therefore, they are downgraded to 'C', as default appears inevitable.

SERVES 2006-1 is a total rate of return collateralized loan obligation (CLO) with a market value termination trigger. The transaction closed on Feb. 24, 2006 and is managed by PPM America Inc.

The following rating actions are effective immediately:

--$157,500,000 class A-1 revolving notes, affirmed at 'B'; Outlook Stable;

--$312,500,000 class A-2 notes, upgraded to 'B' from 'CCC'; Outlook Stable;

--$29,167,000 class B notes, affirmed at 'CC';

--$50,000,000 class C notes, downgraded to 'C' from 'CC';

--$2,080,000 class D-1 notes, downgraded to 'C' from 'CC';

--$2,087,000 class D-2 notes, downgraded to 'C' from 'CC'.

These rating actions reflect the application of Fitch's current criteria which are available at 'www.fitchratings.com' and specifically include the following reports:

--'Fitch Update: Application of Revised Market Value Structure Criteria to TRR CLOs', May 15, 2008.

--'Rating Market Value Structures', April 18, 2008.

--'Global Rating Criteria for Corporate CDOs', April 30, 2008.

Additional information is available at www.fitchratings.com.

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE.

    Source: Fitch Ratings

HOUSTON, Dec. 3 /PRNewswire-FirstCall/ -- ECCO Energy is pleased to announce that it has retained KGC Marketing to assist in its public relations program. KGC is owned by Ken McCormick and is located in Orlando, Florida. Mr. McCormick is a technical analyst and KGC is a marketing firm specializing in small company development. More information may be obtained by visiting KGC Marketing at KGC1.com.

Jack Ozbolt, ECCO's President said, "KGC will provide us with an avenue to get our message to prospective investors and other interested parties. We hope to utilize KGC in the near future."

About ECCO Energy

ECCO Energy is a growing independent oil and gas exploration and production company headquartered in Houston, Texas. The Company is engaged in the acquisition, development and production of oil and natural gas reserves. The Company's primary area of focus is South Texas.

The information may include forward-looking statements, which are subject to known and unknown risks and uncertainties that could cause actual results to differ materially. We refer you to the discussion of risk factors that could affect future operating or financial performance in our most recent prospectus and Form 10-K and other SEC Filings. ECCO Energy assumes no obligation to update any forward-looking statements made here as a result of new information or future events or developments. You will find a reconciliation of any non-GAAP financial measure, as defined by the SEC in Regulation G, to the most directly comparable GAAP number in Reconciliation of Non-GAAP Financial Measures.

Web site: www.eccoenergy.com

SOURCE ECCO Energy Corp